OnKure Therapeutics, Inc. (NASDAQ:OKUR)
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$58.7M
- Net margin
- —
Little or no net debt.
- Total debt
- $926K
- Cash
- $166.5M
- Debt / equity
- 0.01
Comfortably covers what is due within a year.
- Current assets
- $177.7M
- Current liabilities
- $6.6M
- Current ratio
- 26.75
Consumes cash and must keep raising it.
- Operating cash flow
- -$47.8M
- Free cash flow
- -$47.9M
Heavy dilution — shareholders are paying for the business.
- Shares outstanding
- 49.9M
- Share growth (1y)
- 269.2%
- Cash runway
- 42 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
OKUR Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 0.00 | 203.00 K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -203.00 K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A Expense | 4.29 M | 3.91 M | 3.40 M | 3.59 M | 3.71 M | 3.99 M |
| R&D Expense | 12.61 M | 11.71 M | 10.72 M | 11.91 M | 12.61 M | 13.01 M |
| Operating Expenses | 16.90 M | 15.41 M | 14.13 M | 15.50 M | 16.32 M | 17.00 M |
| Operating Income | -16.90 M | -15.62 M | -14.13 M | -15.50 M | -16.32 M | -17.00 M |
| Pretax Income | -15.35 M | -15.16 M | -13.50 M | -14.70 M | -15.39 M | -15.93 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -15.35 M | -15.16 M | -13.50 M | -14.70 M | -15.39 M | -15.93 M |
| EPS (Basic) | -0.31 | -1.11 | -0.99 | -1.09 | -1.14 | -1.19 |
| EPS (Diluted) | -0.31 | -1.11 | -0.99 | -1.09 | -1.14 | -1.19 |
| Shares Outstanding | 49.87 M | 13.67 M | 13.52 M | 13.51 M | 13.51 M | 13.42 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.